The common side effects

The MHRA lists the common side effects of orforglipron as nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain.

That list will look familiar to anyone who has read about semaglutide or tirzepatide. It is the signature of the GLP-1 class, and it follows directly from how these medicines work. GLP-1 slows the rate at which the stomach empties. That is part of what produces the feeling of fullness that makes the medicine effective — and it is also what produces the nausea. The two are not separable.

How common, in numbers

The figures below come from the pooled United States prescribing information, which draws on the ATTAIN weight-management trials. They are a reasonable guide to what to expect, but the UK frequency categories may be presented differently.

Plain-English terms used above correspond to the following label terms: ¹ dyspepsia · ² abdominal distension · ³ eructation · ⁴ gastro-oesophageal reflux disease · ⁵ alopecia. The label reports only the three maintenance doses that were studied — 5.5, 9 and 17.2 mg. It does not report separate figures for the 0.8, 2.5 and 14.5 mg escalation steps.

Two things are worth reading out of that table rather than past it.

The placebo column is not zero. Around one person in ten on a dummy tablet reported nausea, and one in nine reported diarrhoea. Some of what people experience on any medicine would have happened anyway. The meaningful figure is the difference between the columns, not the size of the treatment column on its own.

The relationship with dose is not a straight line. Nausea and vomiting do rise with dose — vomiting nearly doubles, from 13% to 24%. But constipation actually peaks at the middle 9 mg dose at 27% and is lower at the maximum, and indigestion does the same, peaking at 16%. Abdominal pain and headache are essentially flat across the whole range.

This matters for how treatment is managed. It is not simply the case that a higher dose means worse side effects for everything, so someone struggling at 9 mg is not necessarily going to struggle more at 14.5 mg. Equally, a prescriber may hold someone at a dose that suits them rather than pushing to the maximum. These are individual judgements, and the table is the reason they have to be.

Taking all digestive side effects together, around 60–69% of trial participants reported at least one, against 37% on placebo. Severe digestive side effects were much rarer, at roughly 3% versus 1%.

How many people stop because of side effects

This is the honest measure of how tolerable a medicine is, because it reflects what people actually did rather than what they reported.

In the ATTAIN weight-management trials, about 8% of participants overall stopped orforglipron because of side effects, rising to around 10% on the highest dose, against roughly 3% on placebo. Digestive problems specifically accounted for discontinuation in about 3–6% of participants, against 0.7% on placebo.

Put the other way round: roughly nine in ten people who started orforglipron in the trials did not stop because of side effects. That is a reasonable, rather than a remarkable, tolerability profile for this class.

One comparison is available and worth knowing. In ACHIEVE-3, the only head-to-head trial against oral semaglutide, orforglipron caused more digestive side effects, and roughly twice as many participants stopped because of them. It also produced greater reductions in HbA1c and greater weight loss. Better results, more side effects — that trade-off is the substance of the conversation with a prescriber, and anyone presenting orforglipron as simply gentler than the alternatives is not reading the data.

Why the dose is increased so slowly

Orforglipron starts at 0.8 mg and steps up through 2.5, 5.5, 9, 14.5 and 17.2 mg, with a minimum of one month at each level. Reaching the top dose therefore takes at least five months.

That schedule is not caution for its own sake. Digestive side effects are worst when the body first encounters the medicine and again after each increase, and they settle as it adapts. Giving a full month at each step lets that adaptation happen before the next increase. Rushing the escalation is the single most reliable way to make treatment intolerable.

It also means the highest dose is not automatically the goal. If someone is doing well at 5.5 mg and finds 9 mg difficult, staying at 5.5 mg is a legitimate clinical decision, not a failure.

Practical management

None of the following replaces advice from your own prescriber, who knows your history. But these are the measures generally used across the GLP-1 class.

Nausea

• Eat smaller amounts more often rather than large meals. A slowed stomach handles small volumes better.
• Stop eating when you feel full, not when the plate is empty. The signal arrives earlier on this medicine and ignoring it usually causes the nausea.
• Fatty, fried and very rich foods are the most common triggers.
• Plain, dry, starchy foods tend to be tolerated best in the difficult weeks.
• Sip fluids steadily through the day rather than drinking large amounts at once.

Constipation

• Fluid intake matters more than usual, and is easy to let slip when appetite drops.
• Increase fibre gradually. A sudden large increase can worsen bloating.
• Movement helps, and gentle daily activity is more effective than occasional exercise.
• If it persists, ask a pharmacist before buying a laxative — which type suits depends on the pattern.

Diarrhoea and vomiting

• Keep fluids up. Dehydration is the complication that matters here, and it can affect the kidneys.
• Persistent vomiting, or being unable to keep fluids down, needs medical advice rather than waiting it out.

When to seek help rather than manage it yourself

Contact a healthcare professional promptly if you experience:

• Severe, persistent abdominal pain, particularly if it spreads to your back or comes with vomiting — this needs assessment for pancreatitis.
• Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or pale stools — possible gallbladder problems.
• Vomiting or diarrhoea that stops you keeping fluids down.
• Signs of an allergic reaction: swelling of the face, lips, tongue or throat, difficulty breathing, or a widespread rash. Seek emergency help.
• Symptoms of low blood sugar — shakiness, sweating, confusion, palpitations — particularly if you also take insulin or a sulfonylurea.
• A noticeable change in your eyesight, if you have diabetic retinopathy.

Less common but important risks

Thyroid tumours. The US label carries a boxed warning — the most serious warning category the US regulator issues — relating to thyroid C-cell tumours seen in rodent studies. On that basis, orforglipron is contraindicated in the United States for anyone with a personal or family history of medullary thyroid carcinoma, or of multiple endocrine neoplasia syndrome type 2. Whether the UK label carries the same warning is not yet known; several GLP-1 medicines are labelled differently in the UK and the EU. We are not going to tell you either way before the SmPC exists.

Pancreatitis. Reported across the GLP-1 class, and uncommon — in the trials, roughly 0.14 cases per 100 patient-years against 0.04 on placebo. Rare, but serious, which is why the abdominal pain guidance above matters.

Gallbladder disease. Gallstones were reported in about 1% of participants against 0.7% on placebo. Rapid weight loss from any cause raises gallstone risk.

Kidney injury. Reported in 0.2% against 0.05%. It is generally a consequence of dehydration from vomiting or diarrhoea rather than a direct effect on the kidneys, which is why keeping fluids up is not a throwaway instruction.

Low blood sugar. In the type 2 diabetes trials, hypoglycaemia was reported by about 2% of people taking orforglipron against 0.2% on placebo, rising to 7% among those also taking a sulfonylurea, against 0.5% among those who were not. Doses of insulin or sulfonylureas often need reducing.

Anaesthesia and sedation. Because orforglipron delays stomach emptying, there is a risk of stomach contents entering the lungs during a general anaesthetic or deep sedation. Tell any surgical, dental or endoscopy team that you take it, well before the procedure.

Diabetic retinopathy. Rapid improvement in blood glucose control can temporarily worsen existing diabetic eye disease. Anyone with retinopathy should have it monitored.

The interactions that make orforglipron different

This is where orforglipron genuinely departs from the injectable GLP-1s, and it is the part most often left out of articles about it.

Semaglutide and tirzepatide are peptides. They are broken down like proteins and have few drug interactions. Orforglipron is a small molecule, metabolised by the liver enzyme CYP3A4 — which puts it in the same interaction territory as a great many ordinary medicines.

• Medicines that strongly inhibit CYP3A4 — clarithromycin is a common example — substantially raise orforglipron levels, and the dose must be capped.
• Medicines that strongly induce CYP3A4 — carbamazepine, for instance — sharply reduce orforglipron levels, and should be avoided.
• Statins. Orforglipron raises levels of several statins. Simvastatin in particular has a dose cap when the two are taken together.
• Oral contraceptives. Because orforglipron slows stomach emptying, oral contraceptive pills may not be absorbed reliably. Women using oral contraception are advised to switch to a non-oral method, or add a barrier method, for 30 days after starting and for 30 days after every dose increase. With six dose levels, that applies repeatedly through the first five months, not just at the start. This is easily the most commonly overlooked instruction attached to this medicine.
• Insulin and sulfonylureas. Doses may need reducing.

This is not a complete list. Anyone considering treatment should give a prescriber a full list of everything they take — prescribed, bought over the counter, and any supplements.